BioCentury
ARTICLE | Company News

UCSD, RetroSense Therapeutics deal

September 12, 2016 7:00 AM UTC

The university granted RetroSense exclusive, worldwide rights to develop red activatable channelrhodopsin (ReaChR), a next-generation optogene, which RetroSense will use for vision restoration. RetroS...